Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegliposomal doxorubicin + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
pegliposomal doxorubicin + 5-fluorouracil is a combination chemotherapy regimen investigated by the Sixth Affiliated Hospital, Sun Yat-sen University, for the second-line treatment of metastatic gastric cancer. This regimen pairs pegylated liposomal doxorubicin (PLD)—an anthracycline formulation designed to enhance drug delivery to tumor tissues while minimizing cardiotoxicity—with 5-fluorouracil (5-FU), a well-established pyrimidine antimetabolite. Doxorubicin functions by intercalating into DNA and inhibiting DNA topoisomerase II, leading to double-strand breaks and apoptosis, while 5-FU inhibits thymidylate synthase, thereby depleting the nucleotide pools required for DNA synthesis. The combination was evaluated in a Phase II clinical trial (NCT02145559) as a potentially more tolerable and effective alternative to standard second-line agents like irinotecan in patients who have progressed on first-line therapy.
- Other names
- Pegylated liposomal doxorubicin + 5-fluorouracilPLD + 5-fluorouracil
02
Targets
TOP2A (DNA topoisomerase II)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on pegliposomal doxorubicin + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegliposomal doxorubicin + 5-fluorouracil.